Torque’s Glimtor PM1 Tablets contain Glimepiride, a sulphonylurea antihyperglycaemic agent acts mainly by stimulating insulin release from pancreatic beta cells, Pioglitazone, a thiazolidinedione antihyperglycaemic agent acts by a reduction of insulin resistance and Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.
Pharmaceutical Dosage Form:
Tablet
Route of Administration:
Oral
Composition:
Each uncoated bilayered tablet contains:
- Glimepiride I.P. 1 mg
- Pioglitazone Hydrochloride Eq. to Pioglitazone I.P. 15 mg
- Metformin Hydrochloride (as extended release form) I.P. 500 mg
- Excipients q.s.
Mechanism of Action:
Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta-cells. It binds to the sulphonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Indications:
Torque’s Glimtor PM1 Tablets are indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.
Dosage:
As directed by the physician.
Storage:
Store protected from light & moisture, at a temperature not exceeding 30ºC.
Presentation:
10 x 15 Tablets
Side effects:
The following adverse reactions may occur: Lactic Acidosis, Taste Disturbance, Nausea, Vomiting, Diarrhoea, Abdominal Pain, Flatulence, Loss of Appetite, Upper respiratory tract infection, Anaemia, Hypoglycaemia, Hypoaesthesia, Headache, Dizziness, Arthralgia, Back Pain, Haematuria, Erectile Dysfunction
Contraindications:
Torque’s Glimtor PM1 Tablets are contraindicated in patients with: Known hypersensitivity to metformin, glimepiride, pioglitazone or any of the components of this product. Severe renal impairment Acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis Diabetic pre-coma Patients with established NYHA class III or IV heart failure Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory failure, recent myocardial infarction, shock Hepatic insufficiency, acute alcohol intoxication, alcoholism Acute conditions with the potential to alter renal function such as: - Dehydration - Severe infection - Shock - Intravascular administration of iodinated contrast agents Lactation
Drug Interactions:
Alcohol NSAIDs ACE Inhibitors Angiotensin II Receptor Antagonists Diuretics Verapamil Rifampicin Cimetidine, Dolutegravir, Ranolazine, Trimethoprime, Isavuconazole, Fluconazole Vandetanib, Crizotinib, Olaparib Thyroid Stimulating Agents, Glucocorticoids Anabolic Steroids and Male Sex Hormones Gemfibrozil
